POLPHARMA-BIOLOGICS
Polpharma Biologics - a biopharmaceutical company focused on developing and manufacturing biosimilars – announces over 70 new vacancies. The new roles will support the companies advancing pipeline leading to a ramp up of its manufacturing output.
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employees joining, bringing the companies headcount to over 800. They come at a time of rapid growth in the Polish biotechnology sector, with over 50 biological therapeutics being developed in the country.
Polpharma Biologics development and manufacturing is completed at its two Polish sites, a large scale mammalian manufacturing site in Warsaw and a mammalian and microbial facility in Gdańsk. Both sites are looking to recruit for a variety of new roles including in technical development, operations, fill & finish, quality assurance, portfolio management, technology transfer, engineering and IT. Polpharma Biologics also has an innovative research site in Utrecht.
The Polish biotechnology sector has been growing rapidly over the last 10 years with Polish biotech companies all adding new biologics to their pipeline. One of the most advanced includes Polpharma Biologics natalizumab biosimilar for the treatment of Crohn’s disease and multiple sclerosis and their joint venture company Bioeq’s ranibizumab for the treatment of vision loss. This exponential growth has created a huge demand for expertise both home grown and internationally.
Lidia Olowska, VP People and Organisation at Polpharma Biologics commented:
“The new positions have been established due to the rapid progression of our pipeline. Polpharma Biologics is very dynamic, diverse and international organization, attracting talents and experts from all over the world. We are also excited to see the return of many Polish scientists, technicians and engineers who have worked in large biotech abroad, returning to Poland and joining Polpharma Biologics to drive the industry forward and help improving patient’s access to modern therapies.”
About the Polpharma Biologics
The Polpharma Biologics Group creates quality biosimilars with a passion to improve the lives of patients. The group has an extensive and ever-growing pipeline of biosimilars to treat a number of conditions across major therapeutic areas. Many of these biosimilars have already been commercially partnered with the world’s largest biopharmaceutical companies.
The groups has extensive development and manufacturing facilities across Europe, investing not only in laboratories and production lines, but also in know-how, employing over 800 specialists from across the globe.
Learn more at www.polpharmabiologics.com
To view the new vacancies visit: https://polpharmabiologics.com/en/careers/job-search
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005481/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Signs Platinum Partnership with Clearlake Capital to Accelerate Digital Transformation in Private Equity Sector29.10.2025 02:10:00 CET | Press release
FPT, a global leader in digital transformation, announced the signing of a Platinum Partnership Agreement with Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies. This strategic alliance marks a bold step in FPT’s expansion into the private sector, to deliver transformative technology solutions across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028209395/en/ “This Platinum Partnership with Clearlake is a proud milestone in our journey to become a global digital transformation powerhouse - delivering business value and creating lasting impact for the communities we serve through technology,” said Pham Minh Tuan, Executive VP of FPT Corporation and CEO of FPT Software. “We aim to bring cutting-edge, AI-First solutions and services to Clearlake’s portfo
The Estée Lauder Companies Partners with Shopify to Reimagine DigitalBeauty Commerce and Elevate Consumer Experiences28.10.2025 22:26:00 CET | Press release
Partnership with recognized tech leader will enable accelerated innovation and personalized omnichannel experiences The Estée Lauder Companies Inc. (NYSE:EL) today announced a strategic partnership with Shopify Inc., a leading global commerce platform, to modernize its digital technology infrastructure and deliver best-in-class omnichannel consumer experiences. This collaboration will establish a new digital commerce foundation aimed at increasing consumer centricity, fueling sustainable growth, and driving speed and efficiencies at scale across The Estée Lauder Companies’ diverse portfolio of prestige and luxury beauty brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028165887/en/ This breakthrough and first-of-its-kind omnichannel partnership is part of The Estée Lauder Companies’ Beauty Reimagined strategy, which focuses on reaching consumers in smarter, faster, and more personalized ways. Together, The Estée Lau
1888 Studios and Paramount Announce Landmark 10-Year Lease Agreement to Unlock Access to Newly Enhanced Film and Television Tax Incentives28.10.2025 21:35:00 CET | Press release
1888 Studios, a state-of-the-art, 1.6 million square foot film and television production campus in Bayonne, NJ, to be built for movie makers by movie makers, announced today that Paramount, a Skydance Corporation, (“Paramount”) (NASDAQ: PSKY), a leading, next generation global media and entertainment company, has signed a landmark minimum 10-year lease agreement. Paramount has committed to occupy more than 285,000 square feet of the facility, establishing a major production hub in New Jersey. Paramount’s commitment further cements the state as a premier destination for film and television production, backed by a leading tax incentive program. Currently under development by Togus Urban Renewal, 1888 Studios is set to become the largest campus-style production facility in the Northeast and one of the largest in the nation. The 58-acre facility will offer over 1.1 million square feet of production space spanning 23 smart sound stages with a minimum of 40-foot clear ceilings; production su
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations28.10.2025 21:05:00 CET | Press release
Proven, prebuilt AI agents from a leader in responsible AI governance enable first adopter, American Life & Security Corp., to streamline private credit operations SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of its AI agent catalogue for financial services and healthcare firms. The outcome-focused AI agents are designed to simplify complex operations such as credit processing and contract validation. Delivered as a managed service, the agents help organizations overcome talent shortages and operational bottlenecks securely and at-scale. One of the first customers to evaluate an SS&C AI Agent is American Life, a rapidly growing carrier in the annuity and retirement space based in Lincoln, Nebraska. The firm is leveraging and evaluating SS&C’s Credit Agreement Document Agent to streamline processing within its private credit operations. The AI agent continuously reviews and updates lengthy loan documents, cutting time and errors associated with manual revie
Logitech Announces Q2 Fiscal Year 2026 Results28.10.2025 21:05:00 CET | Press release
Operational Excellence and Strategic Priorities Drive Strong Second Quarter SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2026. Sales were $1.19 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q2 of the prior year. GAAP gross margin was 43.4 percent, down 20 basis points compared to Q2 of the prior year. Non-GAAP gross margin was 43.8 percent, down 30 basis points compared to Q2 of the prior year. GAAP operating income was $191 million, up 19 percent compared to Q2 of the prior year. Non-GAAP operating income was $230 million, up 19 percent compared to Q2 of the prior year. GAAP earnings per share (EPS) was $1.15, up 21 percent compared to Q2 of the prior year. Non-GAAP EPS was $1.45, up 21 percent compared to Q2 of the prior year. Cash flow from operations was $229 million. The quarter-ending cash balance was $1.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom